STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1393 by analyst upside · 2026-06-27
TARS
Tarsus Pharmaceuticals, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+49.6%
implied upside to consensus target
Current Price $62.92
Consensus Target $94.11
Bull Target $100.0
Bear Target $88.0
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
8
Hold
0
Sell
0
52-Week Low $38.51
52-Week High $85.25
YTD Return -22.1%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 21.9x
EPS (TTM) $-1.11
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $535M
Profit Margin -9.0%
52-WEEK RANGE
52-Week Low $38.51
52-Week High $85.25
Current Price $62.92
Bear Target $88.0
Bull Target $100.0
● Now $62.92 ● Target $94.11
TRADING DATA
Avg Volume 633K
YTD Return -22.1%
Analyst Count 9
Consensus Buy
Upside to Target +49.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at $62.92 with a Wall Street consensus price target of $94.11, implying potential upside of 49.6% over the next 12 months. 9 analysts currently cover TARS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $88.0.

TARS operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 22.1% year-to-date and is currently trading near the upper end of its 52-week range of $38.51 – $85.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TARS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-02-25 14% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2026-02-25 62% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Mizuho ● Initiated
Outperform 2025-11-20 Building track record
Guggenheim — Reiterated
Buy → Buy 2025-11-05 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-10-20 31% win rate (48 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2025-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →